Apple sues Masimo, saying the medical tech company “carefully studied Apple's IP” during its patent-infringement lawsuit against Apple to make its W1 watches
Blake Brittain / Reuters :
Context & Ripple Effects
Masimo initiated the conflict with a 2020 claim that Apple infringed patents covering blood-oxygen and heart-rate monitoring. Apple’s new action turns that dispute into reciprocal litigation over the technology and design of Masimo’s W1 watches, rather than a one-directional challenge to Apple Watch features.
The fight later produced an ITC finding involving an Apple Watch pulse-oximeter patent, an import-ban appeal by Apple, and a jury award against Apple over a blood-oxygen patent, showing how claims around wearable sensors can affect both product access and damages exposure.
First-order effects
- Masimo must defend Apple’s allegation that it used Apple intellectual property in developing the W1, alongside its own patent claims against Apple.
- Apple gains a separate legal avenue to contest Masimo’s watch ambitions while it defends the Apple Watch’s health-monitoring features.
Second-order effects
- The reciprocal cases raise the cost and complexity of settlement for Apple and Masimo because each company now has claims tied to competing wearable products.
- Rulings over pulse-oximeter technology can shape the parties’ leverage over Apple Watch sales and Masimo’s ability to position the W1 against it.
Third-order effects
- If reciprocal claims become the norm in wearable-health disputes, patent portfolios will function increasingly as competitive tools for limiting rivals’ product options, not solely for collecting licensing revenue.
- The later ITC and jury outcomes indicate that sensor-feature disputes can move from technical infringement claims to remedies with direct consequences for device availability and financial exposure.
The trend: Wearable-health competition is becoming a patent-intensive contest in which sensor features, product access, and litigation leverage are tightly linked.